Pacific Biosciences of California Inc (PACB) saw an uptrend of 5.84% in the recent trading with $1.45 being its most recent. The current price level -46.69% lower than the highest price of $2.72 marked by the stock while trading over the past 52-weeks, whereas it is 70.37% higher than the lowest price of $0.85 the company dropped to over past 52-weeks. The latest news story on PACB appeared in (GlobeNewswire) under the title “PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025” on Today.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 11 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.31 for the stock.
Pacific Biosciences of California Inc Earnings – What Happened With PACB
Coming around sales and income figures on PACB Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Pacific Biosciences of California Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 300.04 million. PACB does have institutional investors; and they hold 65.79% of the stock.
As on 2024-06-30, ARK INVESTMENT MANAGEMENT LLC was the top most holder in Pacific Biosciences of California Inc (NASDAQ:PACB) with an ownership of 33.21 million shares of the company or 12.1932 of the stake worth $45.5 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 9.5449 of the outstanding shares. Its stake is worth $35.62 million for having 26.0 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 8.6674 of the outstanding shares. With this there are now 308.0 institutions which have possession in PACB’s shares.
Key Metrics forPACB
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Pacific Biosciences of California Inc has a debt to equity ratio of 7.63.
